- Geoff Ambler (NSW)
- Phil Bergman (VIC)
- Maria Craig (NSW)
- Cecilia Garcia Rudaz (ACT)
- Mark Harris (QLD)
- Paul Hofman (NZ)
- Ian Hughes (QLD)
- Bin Moore (NSW)
- Aris Siafarikas (WA) Chairperson
- Kate Williams (SA)
- Helen Woodhead (NSW)
How to Join The Committee
Every 2 years there is a call for EOI to join the subcommittee. This message goes out to all APEG members via the monthly e-bulletin, shortly after the Annual General Meeting.
Terms of Reference:
This committee is comprised of Paediatric Endocrinologists, Specialist Nurses, and Researchers in human growth. It succeeds and builds upon the knowledge and experience of the Australasian Growth Hormone Committee and database (OZGROW) and the Growth Hormone Advisory Committee (GHAC).
The aims of the committee are to be the point of contact regarding, and to advocate for, clinical care, therapy and research related to child and adolescent growth. The committee will:
– advise APEG Council on matters relating to child and adolescent growth.
– promote research into child and adolescent growth.
– provide education on child and adolescent growth.
Proposals to Undertake Research Utilizing OZGROW and the OZGROW Database
APEG members and others are encouraged to make use of the OZGROW database for their research. Initial approaches may be made to Dr Hughes to assess the feasibility of a proposed project. Subsequently, a summary of the project and a description of its proposed utilization of OZGROW may be submitted to the Committee via the Chair, Dr Choong. OZGROW has a standard form for such applications and the Committee has drawn up a set of guidelines, which are available to applicants, in assessing these.
Reporting of Adverse Events in Relation to hGH Treatment
An important function of OZGROW is to monitor the short and long term safety of hGH treatment in Australia and New Zealand. OZGROW relies on clinicians observing an adverse event to report that event to OZGROW. There is also a requirement to report adverse events to the Therapeutic Goods Administration (TGA). OZGROW suggests the best way to achieve both these objectives is to fill in the TGA “Report of suspected adverse reaction to medicines or vaccines form” online: https://www.tga.gov.au/form/blue-card-adverse-reaction-reporting-form and email it to both the TGA (email@example.com ) and OZGROW ( firstname.lastname@example.org ).
- OZGROW Diagnosis Codes for use on Application for Growth Hormone and Growth and Treatment record forms (PDF: 89KB)
- The 1st centile height values based on the CDC data (PDF: 139KB)
- OZGROW Annual Report 2005 (PDF: 127KB)
- OZGROW Annual Report 2006 (PDF: 140KB)
- OZGROW Annual Report 2007 (PDF: 172KB)
- OZGROW Annual Report 2009/2010 (PDF: 35KB)
- OZGROW Annual Report 2011 (PDF 158kb)
- A Comparison of Publish Criteria for Assuming Attainment of Adult Height in Girls who have Received Growth Hormone Treatment
- Book Review – Paediatric Endocrinology and Inborn Errors of Metabolism
- An Auxology-based Growth Hormone Program: Update on the Australian Experience
- Gender Bias in Children Receiving Growth Hormone Treatment
- Benefit of Early Commencement of Growth Hormone Therapy in Children with Prader-Willi Syndrome
- Proposed New Target Height Equations for Use in Australian Growth Clinics
- Growth hormone treatment for Turner syndrome in Australia reveals that younger age and increased dose interact to improve response
- Growth Hormone Regimens in Australia: Analysis of the First Three Years of Treatment for Idiopathic Growth Hormone Deficiency and Idiopathic Short Stature
- The influence of secular trend for height on ascertainment and eligibility for growth hormone treatment
- Response to growth hormone treatment in Prader-Willi Syndrome: Auxological criteria vs genetic diagnosis
- Comparison of Centers for Disease Control and Prevention and World Health Organization References/Standards for Height in Contemporary Australian Children: Analyses of the Raine Study and Australian National Children’s Nutrition and Physical Activity Cohorts
- Comparison of weight-vs body surface area-based growth hormone dosing for children: implications for response
The Therapeutic Goods Administration